Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases. Co.'s portfolio includes soluble guanylate cyclase (sGC) stimulators that modulate a key node in a fundamental signaling network in both the central nervous system (CNS) and the periphery. The nitric oxide (NO) sGC cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that controls key aspects of physiology throughout the body. The NO-sGC-cGMP pathway regulates biological functions including mitochondrial function, neuronal function, inflammation, and hemodynamics. The CYCN average annual return since 2019 is shown above.
The Average Annual Return on the CYCN average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CYCN average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CYCN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|